5,966 Danaher Corporation $DHR Shares Acquired by Fulcrum Asset Management LLP

Key Points

• Fulcrum Asset Management increased its Danaher stake by 36.2% in the third quarter, acquiring 5,966 shares and ending the period with 22,425 shares valued at about $5.1 million.
• Danaher reported quarterly earnings of $2.11 per share, beating the $1.92 consensus estimate; revenue was $6.55 billion, up 8.3% year over year but slightly below analyst expectations.
• Analysts gave Danaher a consensus “Moderate Buy” rating, with an average price target of $242.91. The company also paid a quarterly dividend of $0.40 per share.

Fulcrum Asset Management LLP raised its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 36.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,425 shares of the conglomerate's stock after buying an additional 5,966 shares during the period. Fulcrum Asset Management LLP's holdings in Danaher were worth $5,071,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. bought a new stake in Danaher in the second quarter valued at approximately $10,492,520,000. Jupiter Topco LLC bought a new stake in shares of Danaher in the 2nd quarter worth approximately $1,456,317,000. Generation Investment Management LLP purchased a new position in shares of Danaher during the second quarter valued at approximately $1,287,949,000. Bank of America Corp DE purchased a new position in shares of Danaher during the second quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc purchased a new position in shares of Danaher during the second quarter valued at approximately $801,056,000. 79.05% of the stock is owned by institutional investors.

Danaher Trading Up 2.2%

NYSE DHR opened at $235.21 on Tuesday. The stock's 50 day moving average is $220.65 and its 200 day moving average is $201.57. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $165.48 billion, a PE ratio of 38.50, a P/E/G ratio of 2.95 and a beta of 0.76. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating the consensus estimate of $1.92 by $0.19. The business had revenue of $6.55 billion during the quarter, compared to analyst estimates of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The company's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.89 earnings per share. Research analysts forecast that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were paid a dividend of $0.40 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher's payout ratio is presently 26.19%.

Wall Street Analyst Weigh In

DHR has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $240.00 price target on shares of Danaher in a report on Wednesday, July 22nd. Robert W. Baird raised their target price on shares of Danaher from $246.00 to $254.00 and gave the stock an "outperform" rating in a research report on Thursday, October 22nd. Wells Fargo & Company dropped their target price on shares of Danaher from $212.00 to $195.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 22nd. The Goldman Sachs Group reaffirmed a "buy" rating and set a $275.00 target price on shares of Danaher in a research note on Thursday, October 22nd. Finally, TD Cowen boosted their price target on shares of Danaher from $255.00 to $270.00 and gave the company a "buy" rating in a research report on Thursday, October 22nd. Eighteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $242.91.

Insiders Place Their Bets

In other Danaher news, CAO Christopher Bouda sold 7,598 shares of the company's stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total value of $1,782,186.88. Following the sale, the chief accounting officer owned 9,107 shares in the company, valued at approximately $2,136,137.92. This represents a 45.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.80% of the company's stock.

Danaher Company Profile

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing.

The company's businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.